Search
Displaying 351–360 of 665 for “retinitis clinical trial”
-
Eye on the Cure Podcast | Episode 39: Paul Bernstein, MD, PhD
Eye on the CureJanuary 20, 2023. Paul Bernstein, MD, PhD, from the Moran Eye Center, University of Utah, and a member of the Foundation’s Scientific Advisory Board talks to host Ben Shaberman about his clinical practice for retinal disease patients
-
Atsena Therapeutics Developing X-Linked Retinoschisis Gene Therapy
Research NewsThe emerging gene therapy is being designed to more safely reach the fovea
-
Partner News
Acquisition significantly expands Janssen’s eye disease portfolio and strengthens its gene therapy capabilities. Late-stage AMD affects millions of people with no effective treatments currently available .
-
Beacon Stories
Allen has always wanted to be known as an artist, first and foremost. His photography hints at the ever-changing nature of people’s lives and their environment, much like his own progression with retinitis pigmentosa (RP).
-
Sue Lives Life to the Fullest and Wants to Help Others Do the Same
Beacon StoriesMeet Sue Sanger. Sue was diagnosed with retinitis pigmentosa (RP) at the age of 29 but has continued to travel, advance in her legal and political career, and more. In the following story, Sue explains, in her own words, all she has accomplished since learning she has RP and why she’s a supporter and member of the Foundation Fighting Blindness Legacy Society.
-
Foundation Joins the Institute for Gene Therapies, a Newly Formed Advocacy Organization
Research NewsIGT to accelerate gene therapy development and patient access
-
Since its founding in 1971, the Foundation Fighting Blindness has been dedicated to funding innovative research to find preventions, treatments, and cures for inherited retinal degenerative diseases that lead to blindness and affect more than 10 million people in the United States.
-
Funded Grants and Awards for Fiscal Year 2018 (July 1, 2017–June 30, 2018)
-
The My Retina Tracker Registry is a research database of people and families affected by inherited retinal degenerative diseases.
-
Ophthotech to Boost Development of Gene Therapy for Best Disease
Research NewsOphthotech Corporation, a biopharmaceutical company focused on the development of therapies for orphan retinal diseases and age-related macular degeneration, has announced an evolving, commercial partnership with the University of Pennsylvania and University of Florida to develop a gene therapy for Best disease caused by BEST1 mutations.
.png)
